SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091230
Filing Date
2024-08-06
Accepted
2024-08-06 08:41:26
Documents
56
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-20240630.htm   iXBRL 10-Q 1440837
2 EX-31.1 inzy-ex31_1.htm EX-31.1 15681
3 EX-31.2 inzy-ex31_2.htm EX-31.2 16337
4 EX-32.1 inzy-ex32_1.htm EX-32.1 8818
5 EX-32.2 inzy-ex32_2.htm EX-32.2 8944
  Complete submission text file 0000950170-24-091230.txt   5738765

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20240630.xsd EX-101.SCH 842418
59 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20240630_htm.xml XML 818114
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 241177243
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)